Search This Blog

Thursday, April 23, 2026

Kalshi Bans 3 US Politicians For Betting On Their Own Election Races

 by Stephen Katte via CoinTelegraph.com,

Two US congressional candidates and one sitting lawmaker have received fines and bans from Kalshi after they were found betting on the outcomes of their election races, as prediction market platforms crack down on insider trading.

Matt Klein, a sitting member of the Minnesota State Senate, was fined $539 for betting on his primary race in his bid for the US House of Representatives, which is set to take place in August. Ezekiel Enriquez, who ran for a US House seat in March, received a $784 penalty, according to Kalshi's notice of settlement.

Another case involved Mark Moran, a candidate in Virginia's US Senate race, who received a $6,229 penalty and was ordered to return any profits from his trades after allegedly refusing to cooperate with Kalshi to resolve the issue. All three were banned from the platform for five years.

Prediction markets, which let users trade contracts on the outcomes of future events, have faced growing scrutiny over insider trading and possible violations of gambling laws. Kalshi and Polymarket, the two largest platforms, have pledged to introduce stricter controls and crack down on unlawful activity.

Lawmakers offer reasons for insider trades

Moran said in a statement on X that he placed his wager to test Kalshi's procedures and see how the platform would respond to insider trading.

“YES, I did bet ~$100 on myself on Kalshi because I wanted to get caught,” he said, adding that he “wanted to see (1) if Kalshi would come after me and (2) what their path would be.”

Source: Mark Moran

Klein said in a statement that he placed the wager out of curiosity about how prediction markets worked, but later learned it violated platform rules.

“In compliance with their request, I paid a penalty and agreed to be suspended from the platform. That was the only wager I have ever made on a predictions market,” he added.

Klein is a co-sponsor of a bill in the Minnesota Legislature that aims to ban wagers on the outcomes of real-world events such as elections or policy decisions.

Cointelegraph was unable to reach Ezekiel Enriquez for comment.

Kalshi’s ongoing insider trading crackdown

Bobby DeNault, Kalshi's head of enforcement, said Tuesday these cases violated Kalshi's exchange rules but didn't warrant referral to the US Commodity Futures Trading Commission or the Department of Justice for further investigation and prosecution.

“Regardless of the size of a trade, political candidates who can influence a market based on whether they stay in or out of a race violate our rules. No matter how small the size of the trade, any trade that is found to have violated our exchange rules will be punished,” he added.

The platform issued a $2,000 fine and a five-year ban in February to a former California gubernatorial contender for betting on his own candidacy last year.

https://www.zerohedge.com/crypto/kalshi-bans-3-us-politicians-betting-their-own-election-races

'3 Psychiatric Emergencies Most Clinicians Misdiagnose'

 Hello. I’m Dr Adjoa Smalls-Mantey, and I want to talk to you about three psychiatric emergencies that most clinicians misdiagnose: delirium, withdrawal from alcohol and benzodiazepines, and catatonia.

Delirium: Often Mistaken for Psychosis

Delirium is often mistaken for psychosis, mania, or even dementia because patients present with confusion. Missing this diagnosis is very dangerous: Mortality can approach 30%, largely due to the underlying medical causes that are leading to the delirium.

Delirium is an acute change in someone’s consciousness and involve an inability to focus. When you are assessing for delirium, you want to know:

How is the patient right now?

  • What is their consciousness level?
  • What was their mentation like a few hours before? If you have the opportunity to see them again, what it is like at that time?
  • Are they able to focus in a conversation?
  • Do they go off on tangents? One way that you can specifically test for attention is ask someone to count backward or spell a word backward.

Patients with delirium may also have delusions, hallucinations or experience illusions, which may lead someone to think the patient is having a psychotic episode. However, these symptoms may have come on abruptly, and the delusions or hallucinations can be very fantastical and are often visual.

Identifying Underlying Causes 

When you’re checking for delirium, you want to identify any potential underlying causes. Labs that we typically order to determine that include: 

  • Complete metabolic panel
  • Complete blood cell count
  • Urinalysis to rule out a urinary tract infection
  • Toxicology screen
  • Thyroid studies (thyroid-stimulating hormone)

The more common causes of delirium include: 

Medication-Induced Delirium 

Medications are also frequent contributors to delirium, particularly: 

Iatrogenic and Environmental Contributors 

Devices, such as catheters or restraints, can also lead to delirium.

Finally, environmental factors may play a role. Being in a hospital setting can be very disorienting for patients. They may be lacking cues about daylight and time, and they experience frequent sleep interruptions from clinicians coming in to take labs or transfer them to different rooms. Long ICU stays are also associated with delirium.

Differential Diagnosis and Treatment 

When considering delirium, it’s important to keep a broad differential diagnosis and ask what else could explain the presentation. Seizure activity should be considered, including nonconvulsive status epilepticus or a postictal state, and may warrant evaluation with an EEG.

Stroke is another key consideration, particularly when patients present with symptoms such as garbled speech. An important distinction is that stroke typically presents with focal neurologic deficits, which are not seen in delirium.

Other potential diagnoses include central nervous system infection and dementia — though in that case, understanding the time course of cognitive changes is critical. Heat stroke should also be considered in the appropriate clinical context.

The treatment of delirium is treating the underlying cause, whether it’s an infection or a metabolic derangement. Once you correct that, the delirium will improve.

Alcohol and Benzodiazepine Withdrawal

The second psychiatric emergency that clinician often miss is alcohol or benzodiazepine withdrawal. A patient might come in agitated and restless and be experiencing visual hallucinations, so someone might think they are psychotic. Correctly identifying withdrawal is critical because untreated cases can be life-threatening.

Signs of Withdrawal 

The key to identifying alcohol withdrawal is a thorough history. Blood alcohol testing can be helpful, but knowing how much a patient drinks, when they last drank, their usual intake, and any history of complicated withdrawals often provides the clearest hint of how severe that withdrawal can be.

People usually recognize when they’re starting to go into withdrawal. Signs of mild alcohol withdrawal include:

  • Craving a drink to prevent the shakes
  • Anxiety
  • Nausea and vomiting
  • Tremors
  • Hyperactive reflexes
  • Sweating
  • Headache
  • Insomnia
  • Autonomic symptoms (tachycardia and hypertension)
  • Mild agitation

As withdrawal becomes more severe, patients may develop hallucinations, and typically those are visual. Visual hallucinations are not as common in patients with schizophrenia, mania with psychotic features, or depression with psychotic features. It is more common in patients with alcohol withdrawal, benzo withdrawal, and some other disorders.

Severe alcohol or benzo withdrawal can progress to seizures, including grand mal seizures, and delirium tremens, which involves altered consciousness, hallucinations, and marked autonomic hyperactivity with hypertension and sweating.

Assessment and Workup 

When you are assessing for alcohol withdrawal, evaluation includes standard labs, toxicology, an EKG, and a pregnancy test when appropriate. Symptom monitoring with the CIWA-Ar can be helpful, though it is not diagnostic.

In your differential, it is important to consider other causes for the hallucinations, confusion, and agitation, including stimulants such as cocaine, methamphetamines, or bath salts. Also, withdrawal from other substances such as opioids may cause nausea, muscle cramps, abdominal cramps, and rhinorrhea.

If someone is tachycardic with a high blood pressure, could they be having a heart attack? You want to also rule out other acute medical conditions such as pulmonary embolismhyperthyroidism, or infection.

Treatment of Withdrawal 

First-line therapy is benzodiazepines such as: 

In refractory cases, phenobarbital or propofol may be required, often necessitating intubation.

Catatonia: Silent Emergency Clinicians Miss 

The third psychiatric emergency that clinicians often miss is catatonia. Patients may appear depressed or uncooperative, but it is important to consider this diagnosis given the potentially serious consequences if it is overlooked.

Consequences of untreated catatonia include: 

Types of Catatonia 

Catatonia is a behavioral syndrome. It’s the inability to move or not moving even though you have the physical ability to do so.

There are three different types of catatonia: akinetic, hyperkinetic, and malignant. 

The most severe cases of catatonia are malignant catatonia, which used to have mortalities of up to 50% and higher. But with treatment with electroconvulsive therapy (ECT), that mortality has been brought down to about 20%, which is still quite high.

Symptoms of Catatonia 

  • Akinetic: immobility, negativism, mutism, waxy flexibility, and catalepsy
  • Hyperkinetic: echolalia or echopraxia, excitement, hypermotor activity, impulsivity, extreme agitation and combativeness
  • Malignant: rigidity (different from the lead pipe rigidity seen in neuroleptic malignant syndrome, but there is more stupor), autonomic dysfunction (fever, tachycardia, and hypertension)

Diagnosis and Monitoring 

There is no specific test to see if someone has catatonia. It’s more of a rule-out diagnosis. Lab clues may include:

The Bush-Francis Catatonia Rating Scale, which is a 23-point scale, can help assess severity of symptoms and monitor response to treatment.

One of the ways that we rule out catatonia is by doing a lorazepam challenge:

  • Administer a 1- to 2-mg dose of intravenous lorazepam.
  • Assess the patient in 5-10 minutes. Are they moving more spontaneously? Are they talking more?
  • If not, administer a second 1-2 mg dose of intravenous lorazepam and reassess in 5-10 minutes.

Improvement in movement, speech, or reduction in rigidity supports the diagnosis. However, if you don’t see any change in those symptoms with the lorazepam challenge, you can say this is probably not catatonia.

Causes 

Catatonia is associated with:

  • Psychiatric disorders: depression (unipolar or bipolar), and schizophrenia
  • Medication changes: withdrawal or reduction in antipsychotics
  • Autoimmune diseases: anti-NMDA receptor encephalitis and lupus

Treatment 

  • High-dose benzodiazepines
  • ECT for refractory cases

Clinical Takeaway 

Always keep delirium, alcohol and benzodiazepine withdrawal, and catatonia high on your differential when evaluating patients with psychotic symptoms. Missing these underlying medical causes can progress to be fatal in our patients.

Adjoa Smalls-Mantey, MD, DPhil, is an assistant clinical professor of psychiatry at Columbia University and an adjunct assistant professor of psychiatry at NYU Grossman School of Medicine in New York. She serves as president of the New York County Psychiatric Society and has held multiple leadership roles within the New York City district branch. 

https://www.medscape.com/viewarticle/three-psychiatric-emergencies-most-clinicians-misdiagnose-2026a1000bg2

Iran said to confirm Hormuz tolls paid in cash

 The Central Bank of the Islamic Republic of Iran, also known as Bank Markazi, confirmed on Thursday that revenue from tolls collected on ships passing through the Strait of Hormuz has been deposited in cash currency, Fars news agency reported on Friday after obtaining official information.

The confirmation refuted earlier claims that Iran received the payments in cryptocurrency and media speculation about the type of funds received.

Earlier in the day, Second Vice Speaker of the Iranian Parliament Hamid-Reza Haji Babaee announced that the country had received its first revenue from the tolls. The Central Bank's subsequent clarification emphasized that the deposit was made in physical cash, not digital or crypto assets.

https://breakingthenews.net/Article/Iran-said-to-confirm-Hormuz-tolls-paid-in-cash/66136968

Study Warns of High-Risk Group for Fatal Liver Disease

 

  • An estimated 9% of U.S. adults said they had obesity and drank heavily in 2023, according to nationally representative survey data.
  • Age and insurance were linked to prevalence of concurrent heavy drinking and obesity.
  • GLP-1 agents could be a potential treatment option to address both obesity and alcohol use disorder, the researchers suggested.

An estimated 1 in 10 U.S. adults had overlapping heavy drinking and obesity conditions in 2023, a cross-sectional study found.

In a survey of roughly 45,000 U.S. adults representing more than 257 million people, 9% said they had obesity and drank heavily over the past month, while 3.8% said they had both obesity and met criteria for alcohol use disorder (AUD) over the past year, reported researchers led by Bryant Shuey, MD, MPH, of the University of Pittsburgh.

Overlapping heavy drinking and obesity was most common among men ages 35 to 49 (13.6%), women ages 26 to 34 (11.9%), and Black individuals (11.9%). AUD and obesity overlap was highest for men and women ages 26 to 34 (6.2% and 5.1%), people without insurance, and those on Medicaid, the findings in JAMA Internal Medicine showed.

Shuey and colleagues said the findings on this high-risk population call for public health and clinical interventions tailored to younger and middle-age adults, especially the uninsured and those on Medicaid, to prevent liver disease and liver-associated deaths.

Insurance coverage of evidence-based therapies for the two preventable risk factors, which "contribute synergistically" to rising rates of liver disease and death, is also needed, according to the researchers.

"While evidence is limited on concurrent treatment of risky alcohol use and obesity, clinicians should offer interventions that are effective for both conditions, including motivational interviewing, cognitive behavior therapy, and pharmacotherapy," wrote Shuey and colleagues.

Given the effectiveness of GLP-1 drugs "for weight loss and metabolic dysfunction–associated steatohepatitis, expanding access for patients with co-occurring risky alcohol use and obesity may reduce liver disease burden," they argued.

Real-world data have also shown lower AUD-related hospitalization rates for people on GLP-1 drugs, and the researchers pointed to early trial data showing these drugs can help people with AUD reduce their drinking.

"If this finding is confirmed in larger studies, GLP-1 receptor agonists could become a dual therapeutic for risky alcohol use and obesity," the authors suggested.

In their introduction, Shuey and co-authors noted that heavy drinking in people with obesity has become more common in recent decades, but that the prevalence has not been evaluated since the COVID-19 pandemic, a time when multiple reports indicated increases in alcohol abuse and associated complications. Furthermore, the prevalence of obesity and AUD together has not been looked at.

Their study utilized 2023 National Survey on Drug Use and Health data from 45,133 respondents, representing a total weighted population of 257.5 million adults. About half of the survey respondents were women (51.3%), and 61.2% were white, 17.6% were Hispanic, 12.1% were Black, 6.2% were Asian, 2% were multiracial, and 0.4% were Native Hawaiian or Pacific Islander.

Obesity was defined as a body mass index (BMI) of 30 or higher. Past-month heavy drinking was evaluated by the National Institute on Alcohol Abuse and Alcoholism definition (for men: ≥15 drinks per week or ≥5 drinks per day; for women: ≥8 drinks per week or ≥4 drinks per day). Past-year AUD was defined using DSM-5 criteria.

Nearly 100 million adults were estimated to have obesity, around 60 million to drink heavily, and about 30 million to have AUD.

Men and women with obesity ages 65 and older had the lowest rates of heavy drinking (6% and 3%, respectively) and AUD (2.8% and 0.8%).

Stratified by race and ethnicity, Native Hawaiian and Pacific Islanders had the highest overlap with AUD (7.3%). Conversely, Asian adults reported the lowest prevalence for both obesity and heavy drinking (2.1%) and obesity and AUD (1%).

Uninsured adults had a higher prevalence of overlapping obesity and heavy drinking (9.7%) and AUD (4.5%) than insured adults. Adults covered by Medicaid or the Children's Health Insurance Program (CHIP) had the same 4.5% rate of overlapping AUD and obesity. Higher income correlated with higher prevalence of overlapping heavy drinking and obesity but not overlapping AUD and obesity.

The study findings might have been limited by self-reporting bias, and underreporting of AUD may have overestimated rates of heavy drinking, the researchers acknowledged.

Disclosures

The study was supported by NIH grants.

Shuey reported grants from the National Institute on Drug Abuse during the conduct of the study. Co-authors reported grants from or other relationships with various NIH institutes, the CDC, Helmsley Charitable Trust, the Commonwealth of Pennsylvania, the Donaghue Foundation, the Agency for Healthcare Research and Quality, the U.S. Department of Veterans Affairs, the American Medical Association, and the International Alliance for Diabetes Action.

'New Kink in the Link Between GLP-1 Drugs and Cognition'

 Adults whose type 2 diabetes was treated with GLP-1 receptor agonists were more likely to develop cognitive impairment over 10 years than their counterparts not treated with GLP-1 agents, a propensity-matched retrospective study of nearly 65,000 patients suggested.

Durable cognitive impairment -- defined as vascular dementia, Alzheimer's disease, or mild cognitive impairment -- occurred twice as frequently in diabetes patients who used GLP-1 drugs (2.6% vs 1.3%, HR 2.74, P<0.0001), but mortality risk was lower with the drugs (3.9% vs 8.2%, HR 0.68, P<0.0001), according to Isaac Thorman, ScM, an epidemiology researcher at the Johns Hopkins University School of Medicine and a third-year medical student at New York Medical College in Valhalla, and colleagues.

On a compound outcome that assessed both cognitive impairment and mortality, there was no significant difference between GLP-1 receptor agonist users and non-users (6.1% vs 9.1%, HR 0.98, P=0.39), Thorman reported at a late-breaking science session at the American Academy of Neurology annual meeting in Chicago.

Overall, GLP-1 analogs were associated with an increased risk of cognitive impairment, secondary to a larger, protective effect against mortality, Thorman noted.

"We interpret this to mean that GLP-1 analog recipients lived significantly longer than non-recipients, and that they lived long enough for them to develop cognitive impairment," he said.

The findings come on the heels of two phase III trials showing that Alzheimer's patients treated with the GLP-1 agent semaglutide (Rybelsus) had no significant improvement in cognitive or functional decline over 2 years compared with placebo, Thorman noted.

"The apparent survival paradox demonstrated here, plus our unprecedented sample size and long-term follow-up, may explain the non-significance found in the randomized controlled trials," he said.

The idea of repurposing semaglutide to treat Alzheimer's was driven by real-world data and preclinical research. In observational analyses, GLP-1 receptor agonists were tied to a reduced risk of cognitive impairment and dementia, including a lower risk of Alzheimer's diagnoses. The drug class also demonstrated neuroprotective and anti-inflammatory effects in animal models of Alzheimer's disease.

"Our objective was to assess the long-term risk of cognitive impairment associated with GLP-1 analog use in older adults with type 2 diabetes," Thorman said.

Thorman and co-authors studied people ages 50 and older with type 2 diabetes in the TriNetX dataset of patients from 115 healthcare organizations in five countries. People with pre-existing cerebrovascular disease or durable cognitive impairment were excluded from the study. Patients were followed for up to 10 years.

From a sample of 404,084 middle-age and older adults, the researchers matched 64,530 diabetes patients on more than 170 variables, including demographics, vital statistics, comorbidities, and medications prescribed.

A critical distinction between this study and other observational data "is likely in how we accounted for overall patient health," Thorman told MedPage Today. "At baseline and prior to matching, patients receiving GLP-1 analogs were in significantly worse health, with significant elevations in almost every lab value, diagnosis, and medication. After matching, there were few statistically significant differences, and almost all of these differences were devoid of clinical significance."

In women, the mortality protection of GLP-1 agents balanced cognitive impairment risk; whereas in men, it outweighed the risk of cognitive impairment. The researchers also found no overall protective effect of GLP-1 drugs in diabetes patients ages 80 and older.

When patients are in their 80s and are being followed up for another 10 years into their 90s, other comorbidities may influence cognitive deterioration, observed Paul Edison, MD, PhD, of Imperial College London, who wasn't involved with the study.

Whether robust measurements were used to assess cognitive function also is a question, Edison pointed out. "A thorough investigation into these factors is important before reaching a conclusion," he told MedPage Today.

Long-term, prospective surveillance and results from randomized trials remain critical in assessing the risk-benefit ratio of these drugs, Thorman noted. "Caution is advised when interpreting these findings, as causality cannot be inferred from this retrospective analysis," he said.

Disclosures

Thorman reported no conflicts of interest.

Edison reported relationships with Medical Research Council, the Higher Education Funding Council for England, Alzheimer's Research U.K., Alzheimer's Drug Discovery Foundation, Alzheimer's Society U.K., Alzheimer's Association, the Van-Geest Foundation, the European Union, Roche, Pfizer, Novo Nordisk, GE Healthcare, Piramal Life Science/Life Molecular Imaging, Avid Radiopharmaceuticals, and Eli Lilly.